From Thursday, July 19 to Tuesday, September 11, 2018 September 25, 2018 Final deadline has been extended to Noon, October 2, 2018 Abstract submission is now closed.
* The detailed information for preparation of the presentation slides and data will be announced after the notification of the acceptance or rejection.
Please select the most appropriate category for your presentation.
The Program Committee will make the final decision on the presentation categories.
Purpose of application for each session Please refer to the program page for details.
Please select the most appropriate category for your presentation from below and submit your abstract:
The Program Committee will make the final decision on the presentation categories.
01 | Epidemiology | 42 | Postoperative complications |
---|---|---|---|
02 | Pathology | 43 | ERAS |
03 | Molecular biology | 44 | Sentinel lymph node |
04 | Molecular pathology | 45 | Peritoneal dissemination |
05 | Genomics | 46 | CART |
06 | Epigenomics | 47 | Stent placement |
07 | Development of gastric cancer | 48 | Liver metastasis |
08 | Translational research | 49 | Recurrence |
09 | H.pylori | 50 | Early gastric cancer |
10 | Progression of gastric cancer | 51 | Advanced gastric cancer |
11 | Micrometastasis | 52 | Scirrhous gastric cancer |
12 | Intraoperative frozen section | 53 | Gastric stump carcinoma |
13 | Cancer stem cell | 54 | Multiple gastric cancers |
14 | Gastric cancer screening | 55 | Gastric tube cancer |
15 | Endoscopic diagnosis | 56 | Gastric cardia cancer |
16 | IEE | 57 | Esophago-gastric junction cancer |
17 | Endoscopic resection | 58 | Gastric cancer in elderly patients |
18 | Imaging diagnosis | 59 | AFP-producing gastric cancer |
19 | Artificial Intelligence | 60 | EBV-related gastric cancer |
20 | Clinical study | 61 | Gastrointestinal stromal tumor |
21 | Chemotherapy | 62 | Malignant lymphoma |
22 | Neoadjuvant chemotherapy | 63 | Gastric neuroendocrine tumor |
23 | Adjuvant chemotherapy | 64 | Fundic gland type gastric cancer |
24 | Second-line chemotherapy | 65 | Guidelines |
25 | Intraperitoneal chemotherapy | 66 | Clinical pathway |
26 | Molecular targeted therapy | 67 | Postoperative surveillance |
27 | Biomarker | 68 | Long-term survival case after chemotherapy |
28 | Immunotherapy | 69 | Outcome |
29 | Radiation therapy | 70 | Prognostic factor |
30 | Chemoradiotherapy | 71 | QOL assessment |
31 | Conversion surgery | 72 | Nutrition |
32 | Surgery | 73 | Obesity |
33 | Laparoscopic surgery | 74 | Japanese Classification of Gastric Carcinoma |
34 | Robotic surgery | 75 | Multidisciplinary treatment |
35 | Function-preserving surgery | 76 | Palliative therapy |
36 | Cytoreductive surgery | 77 | Team approach |
37 | LECS | 78 | MDT conference |
38 | Surgical navigation | 79 | Medical cooperation |
39 | Postoperative functional assessment | 80 | Oral care |
40 | Postgastrectomy syndrome | 81 | Others |
41 | Perioperative management |
Please understand that the decision on abstract acceptance/rejection and presentation style (oral or poster) is left to the sole discretion of the Congress President.
English
English
English
Title up to 100 characters
Abstract: up to 1600 characters
We invite you to submit applications for travel grants with details as below. Please apply by selecting "Apply" at the time of abstract submission.
The author is required to report applicable COI (Conflict of Interest) by completing the "Conflict of Interest Disclosure" part in the Abstract Submission process.
Abstract Submission is now closed.
Thank you for your submission.
Congress Secretariat
c/o Congress Corporation
Kohsai Kaikan Bldg.
5-1, Kojimachi, Chiyoda-ku, Tokyo, 102-8481, Japan
Tel: +81-3-5216-5318 Fax: +81-3-5216-5552
E-mail: jgca2019@congre.co.jp